During the past 10 years, substantial progress has been made in the discovery and development of small molecule glutamate carboxypeptidase II (GCP II) inhibitors. These inhibitors have provided the necessary tools to investigate the physiological role of GCP II as well as the potential therapeutic benefits of its inhibition in neurological disorders of glutamatergic dysregulation. This review article details key GCP II inhibitors discovered in the last decade and important findings from preclinical and clinical studies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.drudis.2007.07.010 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!